Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Evaluating the Healthcare Capacity of America’s Largest Travel Destinations : Say Yes To Travel

Alex Bittner is a certified Physician’s Assistant and the President & Assistant Medical Director of AM~PM DOC. He has worked with clients from all over the world in numerous hotels as an on-call house doctor. They have been offering five star medical service for years, working with the top hotels as well as high-profile…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Evaluating the Healthcare Capacity of America’s Largest Travel Destinations : Say Yes To Travel

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Alex Bittner is a certified Physician’s Assistant and the President & Assistant Medical Director of AM~PM DOC. He has worked with clients from all over the world in numerous hotels as an on-call house doctor. They have been offering five star medical service for years, working with the top hotels as well as high-profile patients.

As the pandemic started and travel restrictions started falling into place, it was pretty clear that the United States was going to be hit pretty hard. Hindsight is always 20/20. Could we have locked down earlier? Sure? But we have never been in this situation before. Instead of focusing on what we could have done better or faster, it is important to focus what we can do now.

Businesses being closed and travel restrictions are not an over-reaction. It is appropriate. Again, this is a situation that we have never been in before, so it is paramount that we are cautious and following the guidelines of the WHO, CDC, and the government. How long it will take to “flatten the curve” depends on so many factors, but it is important to follow Stay At Home orders to help alleviate the medical system, minimize exposure, and ultimately passing on the virus.

Interestingly enough, when we think about the medical industry, many of us assume it is insanely busy everywhere. But that is not the case. ER volume is down in smaller markets, like in Cleveland. People are scared to seek medical attention for things that are not coronavirus-related. So the medical system is in an interesting place right now. It is operating at max capacity in hotspots like New York City, but in other cities, not as much.

Ultimately, there is no vaccine yet, and that is where we stand. Or course, there has been talk about different medications, such as the famed Malaria drug. But it is always important to remember that with every medication, there are side effects. Prescribing any sort of medication must be carefully weighed. Currently this Malaria drug is not a sure thing, as testing is still underway.

There have been so many misconceptions regarding the virus. From age to chronic health conditions, there hasn’t been one factor that guarantees you will be sick. As our understanding of this disease has changed, and continues to change, we have to remember that no one is immune to it. On the other side of things, we have to remember that is not an automatic death sentence if you get it. We have to keep things in perspective.

Alex left us with some great advice:

Remember, the best thing is to avoid contact with other people. Be aware of what you are touching, from items to your face. Wash your hands often. And use common sense. It is OK (even encouraged) to be outside to get fresh air and to work out, just be mindful of being around others.

For more info on Alex and his company, check out:

888 AM~PM DOC Toll Free Emergency Hotline

www.ampmdoc.com

https://www.instagram.com/dabittnah/

Say Yes To Travel has a new episode every Thursday!

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512